Chelsea Therapeutics Settles Investor Class Action For $5.5M
Chelsea Therapeutics International Inc. has agreed to pay $5.5 million in cash to settle an investor's putative securities class action stemming from alleged misstatements about its blood pressure drug Northera, the...To view the full article, register now.
Already a subscriber? Click here to view full article